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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine is Black Cohosh effective
for reducing anxiety/depression symptoms in postmenopausal women?
DESIGN: Review of three English language primary randomized controlled studies published
from 2005-2009.
DATA SOURCES: Randomized, double blind, placebo-controlled trials comparing Black
Cohosh to placebo or hormonal therapies were found using PubMed and Cochrane databases.
OUTCOMES MEASURED: Each of the three trials assessed the efficacy and clinical
improvement in anxiety symptoms with the use of Black Cohosh. Studies utilized to measure
change in anxiety symptoms included Harrison Anxiety Rating (HAM), Symptom Rating Test
(SRT), and Kupperman Test.
RESULTS: Two double-blind randomized controlled trials were included in this review. Results
from the Amsterdam et al study indicates that Black Cohosh use had little vasomotor or
anxiolytic activity, however the sample size in this study was small. The second study by Nappi
et al concluded that after the use of Black Cohosh reduced anxiety/depression as well as
vasomotor symptoms in postmenopausal women to the same degree as hormone therapy. The
third study by Vermes et al showed a reduction in anxiety/ depression symptoms. The
Kupperman index scores also decreased over the duration of the study. All three trials
demonstrated that Black Cohosh does contribute reduction in anxiety/depression in menopausal
women.
CONCLUSIONS: All of the RCT and Clinical Trial demonstrate that Black Cohosh use is
effective at reducing anxiety/depression. Black Cohosh seems to be the same effectiveness as
Hormonal therapy available for anxiety/depression in postmenopausal women.
KEY WORDS: Black Cohosh (Remifemin, Cimicifuga racemosa) , anxiety, depression
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INTRODUCTION
Menopause is defined as occurring 12 months after your last menstrual period and marks
the end of menstrual cycles. Menopause can happen in your 40s or 50s. Postmenopausal is after
one has undergone menopause. There are many symptoms associated with menopause, such as
anxiety and depression that can make life challenging.1 Anxiety can be described as a sense of
foreboding, such as feeling as if something is wrong. Women can experience palpitations,
shortness of breath, trembling, lightheadedness, as well as other symptoms due to anxiety.2
Additionally, women approaching menopause are at increased risk for depression, which may be
from hormonal changes.2 This paper evaluates two randomized, double blind control trials and
one clinical trial comparing the efficacy of Black Cohosh to placebo/ hormone replacement
therapy.
Anxiety and Depression in postmenopausal women is relevant to the Physician Assistant
profession due to its high rates of prevalence today. It is estimated that 65% - 85% of women
experience vasomotor symptoms related to menopause, and 30% seek medical attention for these
symptoms.2 Although vasomotor symptoms are most pronounced during the initial years of
menopause, nearly 64% of women will continued to experience vasomotor symptoms up to 5
years after menopause, and 26% of women will have symptoms lasting up to 10 years.1
Currently Black Cohosh is highly affordable since it is available without a prescription. The cost
of a one-month supply of the product ranges from $16 to $60 depending upon the dosage.1
Hormone replacement therapy (HRT) has been the mainstay for treatment.
Benzodiazepine have become treatment of choice for anxiety symptoms, despite the presence of
BZ-induced dependence and antidepressant-induce sexual side effects, weight gain, and
withdrawal. These side effects are why women are seeking alternative medicine, Black Cohosh,
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remedies for their climacteric symptoms.2
Menopause can cause a number of physical changes that may cause anxiety themselves.
It is well known that menopause appears to increase risk for panic attacks but the cause and
effect is not exactly clear. Menopausal anxiety can be hormone mediated, hormone exacerbated,
or simply menopausal related. 1
Usual methods used to treat menopausal anxiety include Hormone Replacement
Therapy, such as Medroxyprogesterone. Additionally, antidepressants are used in combination
with Hormonal Replacement Therapy, such as, fluoxetine, paroxetine, and venlafaxine, can be
used to control anxiety and other menopausal symptoms. Among the pharmacological treatment,
benzodiazepines, Xanax, are the drug of choice for anxiety in postmenopausal women. Also,
other Complementary Alternative Medications, dong quai, black cohosh, St. Johns wort, and
ginkgo biloba, are becoming popular due to the side effects of pharmacologic treatment.3
The above treatments are effective options for postmenopausal women suffering from
anxiety and efficacy of the treatment varies from patient to patient. Women with comorbidities
or history of past breast or uterine cancer, blood clots, liver disease, and stroke are not good
candidates for Hormone Replacement Therapy. Black Cohosh may be a natural anxiolytic
alterative to these regimens in reducing anxiety in postmenopausal women and will be discussed
further in this review.3
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Does Black
Cohosh improve anxiety/ depression symptoms in women who are postmenopausal?”
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METHODS
The three studies utilized in this review include two randomized control trials and
one clinical trial, which met the following criteria: The population consisted of
postmenopausal women with symptoms of anxiety. The intervention used was Black
Cohosh 64mg, 40mb/day. The treatment group receiving Black Cohosh versus the
experimental group receiving either visually matched placebo or HRT.3,4 Outcomes
measured include the efficacy of Black Cohosh for the treatment of Anxiety or
depression incidences in postmenopausal women.
Key word used to locate the literature consisted of Black Cohosh (Black Cohosh
(Remifemin, Cimicifuga racemosa) , anxiety, and depression. All articles were published
in English and published in peer-reviewed journals. The articles were searched via
PubMed and were selected based on their relevance to my clinical question and if they
included patient oriented outcomes (POEMS). Inclusion criteria consisted of randomized
controlled trials and clinical trials with postmenopausal women. Exclusion criteria consist
of previous hormone therapy or contraindications to hormonal therapy. Statistics that
were reported and utilized are relative risk reduction (RRR), absolute risk reduction
(ARR), numbers needed to treat (NNT), Standard Deviation, p-values, baseline tests,
ANOVA.3,4,5

Demographics and characteristics of the studies utilized for review are displayed in Table 1.
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Study

Type

# Pts

Age

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Amsterdam
(2009)

Randomized
Control Trial

34

>40

-Women who were either
postmenopausal for more
than 12 months or perimenopausal [with
amenorrhea lasting 2 to
11 months in the
proceeding year] were
included
-Women with prior
hysterectomy an
uncertain menopausal
status had a serum follicle
stimulating hormone
level greater than or equal
to 40 mIU/l.
other CAM remedies,
oral estrogen, estrogen
cream, or phyto-estrogen
preparation was not
permitted. Perimenopausal women
employed a medically
proven, nonhormonal
form of contraception and
had a negative pregnancy
test.

Axis I diagnosis of
Major Depressive
Disorder, Bipolar
Disorder, Panic
Disorder Phobic
Disorder, Obsessivecompulsive
Disorder, Posttraumatic Stress
Disorder, Acute
Stress Disorder,
Substance- induced
Anxiety Disorder,
Schizophrenia,
Dementia, or
Substance Abuse or
Dependence
Disorder within the
preceding 3 months.

6

-64 mg Black cohosh
BID for first 2 weeks
-4 capsules daily of
128 mg Black cohosh
by study week 4 with
less than or equal to
50% reduction in total
baseline HAM-A score.

Nappi
(2005)

Randomized
Control Trial

64

4555

-Spontaneous menopausal
status of at least 6 months
with follicle- stimulating
hormone [FSH] level >
30 mUI/l
-Presence of hot flushes
[atleast fiver per day] and
endometrial thickness <5
mm.

Previous hormone
therapy or
contraindications to
hormonal treatments

4

40 mb/day of
isopropanolic aqueous
CR extract for 3
months

Vermes
(2005)

Clinical Trial

2016

4565

Kupperman index (20),
refusal or
contraindication for
estrogen therapy

Pts on HRT

140

Remifemin tablets BID
PO x 12 weeks
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OUTCOMES MEASURED
All outcomes measured in the trials were based on patient oriented evidence that assessed
the efficacy and clinical improvement in anxiety as well as other menopausal symptoms in
women. The Amsterdam et al study primarily used HAM-A scores between the two groups to
measure outcomes. Secondary outcomes used in Amsterdam et al study included Beck Anxiety
Inventory (BAI) and Green Climacteric Scale (GCS).3 Nappi et al measured the change in
anxiety and depression using the Symptoms Rating Test (SRT).4 Lastly, Vermes et al also used
the Kupperman index, which utilized the severity of the symptoms. This was evaluated at the
start of the study and throughout the study.5
RESULTS
The results for the Amsterdam et al study was that 34 patients were originally enrolled in
the study and 6 patients were screen failures who withdrew consent to participate. The patients
were randomized to either black cohosh or placebo. 75% of patients completed all study visits
and were used for the results. The final results of the study showed that the HAM-A score at
study endpoint had no significant difference. There was a greater reduction in total GCS scores
favoring placebo (-4.45 (95% CI= (-8.59, 3.12; p= 0.035)).3

Table 2 Characteristics of Black Cohosh and Placebo groups

Caucasian (%)

Black Cohosh
(n=15)

Placebo (n=13)

p-value**

71.43

61.54

0.78
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Age (years) * †

56.7 (6.53)/50-76

50.8 (3.22)/47-57

0.0064

Age at onset of GAD (years)
*

43.6 (8.6)/19-53

44.9 (11.4)/10-55

0.36

Episode Duration (months) *

60.7 (91.6)/5-180

27.9 (29.4)/4-108

0.11

Illness Duration (years) * †

13.1 (12.1)/1-42

6.7 (10.7)/1-39

0.032

Number prior GAD Episodes
*

6.3 (20.5)/0-80

1.3 (2.9)/0-10

0.30

Baseline HAM-A Score *

16.9 (3.8)/10-22

15.9 (3.5)/9-22

0.39

Baseline BAI Score *

11.8 (6.7)/3-26

14.1 (8.6)/5-36

0.66

Baseline PGWB Score *

112.4 (19.5)/84-142

115.2 (24.1)/76158

0.75

*Mean (SD)/range; **Pearson x2 test (binary variables) or Wilcoxon Rank sum test
(continuous variables)

Table 3: Estimated difference in Overall change for treatment groups using regression model

Outcome

Est. Change Diff in Groups
(60β)

95% CI for Change
Diff

p
value

HAM-A

−1.58

−4.53 to 1.37

0.294

BAI

−1.07

−6.14 to 1.96

0.578

GCS total

−4.45

−8.59 to −3.12

0.035

GCS
psychological

−2.68

−5.51 to .15

0.063

GCS anxiety

−1.52

−3.44 to .4

0.121

GCS depression

−1.17

−2.76 to .42

0.148

PGWB

11.06

−3.63 to 25.75

0.140
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Table 4: Estmated values in overall change for treatment groups using regression model (2)
Outcome

Est. Change Diff Cohosh

Est. Change diff Placebo

Effect Size

p value

HAM-A

-2.56

-4.90

0.72

0.294

BAI

-1.17

-4.46

0.34

0.578

GCS Total

0.56

-3.94

0.85

0.035

GCS

0.0084

-1.93

0.55

0.121

-0.19

-0.98

0.54

0.148

anxiety
GCS
depression

Table five for the Nappi et study shows the baseline characteristics of the women treated with
Black Cohosh (CR) and low dose TTSE.

Table 5 [CR (n = 32)] [TTSE2 (n = 32)] p Value
Age (years)

50.5+/- 2.1

50.9 +/- 1.8

0.37

Menopause (months)

9.0 +/- 2.9

9.1 +/- 3.0

0.87

Body Mass Index

22.9 +/- 2.2

22+/- 2.1

0.40

Patel:	
  Black	
  Cohosh	
  and	
  Anxiety/	
  Depression	
  	
  10	
  
	
  

As shown in Figure 1 Black Cohosh (CR) was significantly effective in reducing both anxiety
(p< 0.001) and depression (p< 0.001) measured by SRT following three months of treatment

Figure 14
The results for the Vermes et al study showed that the Kupperman index scores decreased
through the course of the study. The decline was most extreme during the first 4 weeks of
treatment. The total mean score decreased at a constant rate of from one evaluation period to the
next, decreasing first at 8.12, then by 5.56, and finally by 3.96 points.5

Table 6. Changes in the Kupperman Menopause Index in the Course of Treatment
Symptom Week 0
Anxiety

1.77

Week 4
3.53

1.29

Week 8
2.57

0.96

Week12
1.92

0.77

1.53
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Mean/SD

0.021

0.042

0.019

0.038

0.017

0.033

0.016

0.032

Discussion
Many menopausal and postmenopausal women are searching for CAM remedies to
relieve their menopause related symptoms. CAM therapies are becoming more popular due to
their decreased concern about drug toxicity and side effects, cultural attitudes, and the stigma of
having a psychological disorder.3,5 The primary solution for the symptoms of menopause is
HRT, however, many patients are afraid of the risk of breast cancer and deep vein thrombosis
associated with it.5 Nappi et al. compared the efficacy of Black Cohosh compared to HRT in
reducing menopausal symptoms and found a significant reduction in menopause-related
psychological symptoms. Nappi et al. study was limited by the absence of a placebo group.4
With the Amsterdam et al. study there are several caveats that need to be considered in their
findings. There was a lower than expected subject enrollment and small sample size with limited
ability to detect difference between treatment condition, which provides no clinical
meaningfulness.3 Additionally, in the Vermes et al. study the Kupperman index was used and a
mean 17.64 point decrease was observed during the twelve weeks of treatment. This finding is
suggestive that the extract of C racemosa (Remifemin) reduces the intensity of menopausal
symptoms effectively. Additionally, drug tolerability was considered excellent by the patients
themselves and their physicians. The limitations for Vermes et al. study include that the study
was not a placebo-controlled trial. Second, he findings were based on an assessment of changes
in subjective symptoms rather than objective symptoms. 5
Conclusion
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According to the Amsterdam et al. study Black Cohosh appears to be effective in
reducing the vasomotor symptoms of menopause and minimal activity for anxiolytic symptoms.
However, Amsterdam et al. study noted that the sample size was extremely small, and the choice
of Black Cohosh preparation dosage had limited their ability to identify the clinical
meaningfulness of Black Cohosh over placebo.3 Nappi et al. study concludes that Black Cohosh
(40mg/day) can be considered a consistent and safe option to counteract specific symptoms in
postmenopausal women.4 In conclusion Vermes et al. study states that Remifemin may
effectively reduce the severity of symptoms of menopause and Remifemin shows promise as an
effective therapeutic choice for menopausal complaints. 5
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